<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Investor Target Analysis - ER Minoxidil Project</title>
    <style>
        body {
            font-family: 'Helvetica Neue', Arial, sans-serif;
            line-height: 1.7;
            max-width: 1000px;
            margin: 0 auto;
            padding: 40px 30px;
            color: #2c3e50;
            background-color: #fafafa;
        }
        h1 {
            color: #1a5f7a;
            text-align: center;
            font-size: 2em;
            margin-bottom: 10px;
        }
        .subtitle {
            text-align: center;
            color: #666;
            font-size: 1.1em;
            margin-bottom: 40px;
        }
        h2 {
            color: #c0392b;
            border-bottom: 3px solid #c0392b;
            padding-bottom: 10px;
            margin-top: 50px;
        }
        h2.target {
            color: #27ae60;
            border-bottom: 3px solid #27ae60;
        }
        h3 {
            color: #2980b9;
            margin-top: 30px;
        }
        h4 {
            color: #34495e;
            margin-top: 20px;
        }
        table {
            border-collapse: collapse;
            width: 100%;
            margin: 20px 0;
            background: white;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }
        th, td {
            border: 1px solid #ddd;
            padding: 12px 15px;
            text-align: left;
        }
        th {
            background-color: #34495e;
            color: white;
        }
        th.avoid {
            background-color: #c0392b;
        }
        th.target {
            background-color: #27ae60;
        }
        tr:nth-child(even) {
            background-color: #f8f9fa;
        }
        .avoid-box {
            background-color: #fadbd8;
            border-left: 5px solid #c0392b;
            padding: 20px;
            margin: 20px 0;
            border-radius: 0 8px 8px 0;
        }
        .target-box {
            background-color: #d5f5e3;
            border-left: 5px solid #27ae60;
            padding: 20px;
            margin: 20px 0;
            border-radius: 0 8px 8px 0;
        }
        .info-box {
            background-color: #e3f2fd;
            border-left: 5px solid #2196f3;
            padding: 20px;
            margin: 20px 0;
            border-radius: 0 8px 8px 0;
        }
        .strategy-box {
            background-color: #fff3e0;
            border-left: 5px solid #ff9800;
            padding: 20px;
            margin: 20px 0;
            border-radius: 0 8px 8px 0;
        }
        .tier-badge {
            display: inline-block;
            padding: 4px 12px;
            border-radius: 15px;
            font-size: 0.85em;
            font-weight: bold;
            margin-left: 10px;
        }
        .tier-1 {
            background-color: #27ae60;
            color: white;
        }
        .tier-2 {
            background-color: #3498db;
            color: white;
        }
        .tier-3 {
            background-color: #9b59b6;
            color: white;
        }
        ul, ol {
            margin: 15px 0;
            padding-left: 25px;
        }
        li {
            margin: 8px 0;
        }
        hr {
            border: none;
            border-top: 2px solid #eee;
            margin: 40px 0;
        }
        .recommendation {
            background: linear-gradient(135deg, #27ae60, #2ecc71);
            color: white;
            padding: 25px;
            border-radius: 12px;
            margin: 30px 0;
        }
        .recommendation h3 {
            color: white;
            margin-top: 0;
        }
        .source-list {
            background-color: #f8f9fa;
            padding: 15px 20px;
            border-radius: 8px;
            margin-top: 40px;
            font-size: 0.9em;
        }
        .source-list h4 {
            margin-top: 0;
        }
        .pitch-angle {
            background-color: white;
            border: 2px solid #27ae60;
            border-radius: 8px;
            padding: 20px;
            margin: 15px 0;
        }
        .pitch-angle h4 {
            color: #27ae60;
            margin-top: 0;
        }
    </style>
</head>
<body>

<h1>Investor Target Analysis</h1>
<p class="subtitle">Strategic Fundraising for ER Minoxidil (Lipid Matrix) Project</p>
<p style="text-align: center; color: #666;">Date: February 5, 2026</p>

<div class="info-box">
    <h4 style="margin-top: 0;">Strategic Objective</h4>
    <p>Identify venture capital and growth equity investors who:</p>
    <ol>
        <li><strong>Are NOT invested in Veradermics</strong> (avoid conflict of interest)</li>
        <li><strong>Have competitive motivation</strong> to back an alternative play in the hair loss market</li>
        <li><strong>Understand specialty pharma / compounding</strong> business models</li>
        <li><strong>Can move quickly</strong> on smaller check sizes ($500K - $5M seed/Series A)</li>
    </ol>
</div>

<hr>

<h2>Veradermics Investors (AVOID)</h2>

<div class="avoid-box">
    <p><strong>Do not approach these investors.</strong> They have existing positions in Veradermics and would have conflicts of interest. They may also share information with Veradermics management.</p>
</div>

<table>
    <tr>
        <th class="avoid">Investor</th>
        <th class="avoid">Role in Veradermics</th>
        <th class="avoid">Stake / Notes</th>
    </tr>
    <tr>
        <td><strong>Suvretta Capital Management</strong></td>
        <td>Led Series B ($75M) and Series C ($150M)</td>
        <td>Major shareholder - primary financial backer</td>
    </tr>
    <tr>
        <td><strong>Longitude Capital</strong></td>
        <td>Series B participant, IPO investor</td>
        <td><strong>10.7%</strong> - Largest post-IPO shareholder</td>
    </tr>
    <tr>
        <td><strong>SR One</strong></td>
        <td>Early-stage investor</td>
        <td><strong>5.9%</strong> - Second largest shareholder</td>
    </tr>
    <tr>
        <td><strong>Surveyor Capital</strong> (Citadel)</td>
        <td>Series B participant</td>
        <td>Hedge fund arm of Citadel</td>
    </tr>
    <tr>
        <td><strong>Wellington Management</strong></td>
        <td>IPO allocation</td>
        <td>~$30M indicated interest at IPO</td>
    </tr>
    <tr>
        <td><strong>Eli Lilly</strong></td>
        <td>Strategic IPO investment</td>
        <td><strong>4.9%</strong> stake - potential acquirer</td>
    </tr>
    <tr>
        <td><strong>JW Childs Associates</strong></td>
        <td>Early-stage investor</td>
        <td>PE firm, participated in early rounds</td>
    </tr>
    <tr>
        <td><strong>Connecticut Innovations</strong></td>
        <td>Early-stage investor</td>
        <td>State VC fund (Veradermics is CT-based)</td>
    </tr>
    <tr>
        <td><strong>Osage University Partners</strong></td>
        <td>Series B participant</td>
        <td>University tech transfer fund</td>
    </tr>
    <tr>
        <td><strong>PhiFund</strong></td>
        <td>Series B participant</td>
        <td>Healthcare-focused fund</td>
    </tr>
</table>

<hr>

<h2 class="target">Target Investors</h2>

<h3>Tier 1: Best Strategic Fit <span class="tier-badge tier-1">HIGH PRIORITY</span></h3>

<div class="target-box">
    <p><strong>These funds have the right thesis, are NOT in Veradermics, and have appetite for differentiated specialty pharma plays.</strong></p>
</div>

<table>
    <tr>
        <th class="target">Fund</th>
        <th class="target">Why Target</th>
        <th class="target">AUM / Stage</th>
        <th class="target">Pitch Angle</th>
    </tr>
    <tr>
        <td><strong>RA Capital</strong></td>
        <td>Crossover investor known for backing novel therapeutics with differentiated approaches</td>
        <td>~$10B+; Late seed to public</td>
        <td>Lipid matrix = scientifically differentiated, de-risked by existing minoxidil data</td>
    </tr>
    <tr>
        <td><strong>OrbiMed</strong></td>
        <td>Largest healthcare VC ($19B AUM) - conspicuously ABSENT from Veradermics cap table</td>
        <td>$19B; All stages</td>
        <td>They passed on Veradermics for a reason - may want competitive exposure</td>
    </tr>
    <tr>
        <td><strong>Deerfield Management</strong></td>
        <td>Life sciences investor with flexible structures, appetite for specialty pharma</td>
        <td>~$14B; Growth/crossover</td>
        <td>503B compounding = capital-efficient, fast path to revenue</td>
    </tr>
    <tr>
        <td><strong>Versant Ventures</strong></td>
        <td>Biotech specialist, early and growth stage, backs platform technologies</td>
        <td>~$5B; Seed to Series B</td>
        <td>Lipid matrix platform could extend to other APIs</td>
    </tr>
    <tr>
        <td><strong>5AM Ventures</strong></td>
        <td>Life sciences focus, therapeutic innovation, company building expertise</td>
        <td>~$1.5B; Early stage</td>
        <td>Novel formulation approach, strong IP defense story</td>
    </tr>
</table>

<div class="pitch-angle">
    <h4>Pitch Framework for Tier 1 Funds</h4>
    <ol>
        <li><strong>Market validation:</strong> Veradermics just IPO'd at $256M proving market demand</li>
        <li><strong>Differentiation:</strong> Lipid matrix ≠ HPMC gel = freedom to operate</li>
        <li><strong>Capital efficiency:</strong> 503A/503B path = $8-21K to first patient vs. $50M+ for NDA</li>
        <li><strong>Speed:</strong> 8-10 weeks to human data vs. years for FDA approval</li>
        <li><strong>Optionality:</strong> Can stay compounding OR pursue 505(b)(2) NDA later</li>
    </ol>
</div>

<h3>Tier 2: Hair Loss Market Competitors <span class="tier-badge tier-2">STRATEGIC</span></h3>

<div class="target-box">
    <p><strong>These funds invested in Pelage Pharmaceuticals ($120M Series B for hair loss treatment) - they're already betting on the hair loss market and may want portfolio diversification.</strong></p>
</div>

<table>
    <tr>
        <th class="target">Fund</th>
        <th class="target">Pelage Role</th>
        <th class="target">Why They'd Be Interested</th>
    </tr>
    <tr>
        <td><strong>ARCH Venture Partners</strong></td>
        <td>Led Pelage $120M Series B</td>
        <td>Already bullish on hair loss market; Pelage is topical (different MOA), would diversify with oral ER play</td>
    </tr>
    <tr>
        <td><strong>GV (Google Ventures)</strong></td>
        <td>Pelage investor</td>
        <td>Tech-forward, likes data-driven approaches; our PK differentiation story resonates</td>
    </tr>
    <tr>
        <td><strong>Main Street Advisors</strong></td>
        <td>Pelage investor</td>
        <td>Consumer health focus; oral minoxidil has strong consumer pull</td>
    </tr>
    <tr>
        <td><strong>Visionary Ventures</strong></td>
        <td>Pelage investor</td>
        <td>Strategic investor; may want multiple shots on goal in hair loss</td>
    </tr>
    <tr>
        <td><strong>YK Bioventures</strong></td>
        <td>Pelage investor</td>
        <td>Biotech focused; understands formulation differentiation</td>
    </tr>
</table>

<div class="pitch-angle">
    <h4>Pitch Framework for Tier 2 (Pelage Investors)</h4>
    <ol>
        <li><strong>Portfolio hedge:</strong> Pelage is topical/regenerative; we're oral ER - different mechanisms, different patients</li>
        <li><strong>Faster timeline:</strong> Pelage Phase III in 2026; we can have revenue in 2026 via compounding</li>
        <li><strong>Lower risk:</strong> Minoxidil is FDA-approved drug; Pelage is novel therapeutic</li>
        <li><strong>Competitive intelligence:</strong> Gives them insight into Veradermics' competitive landscape</li>
    </ol>
</div>

<h3>Tier 3: Specialty Pharma / Compounding Angle <span class="tier-badge tier-3">ALTERNATIVE</span></h3>

<div class="info-box">
    <p><strong>These funds understand specialty pharma business models and may appreciate the 503A/503B compounding pathway as a capital-efficient market entry strategy.</strong></p>
</div>

<table>
    <tr>
        <th class="target">Fund</th>
        <th class="target">Focus</th>
        <th class="target">Why Target</th>
    </tr>
    <tr>
        <td><strong>Frazier Healthcare Partners</strong></td>
        <td>Specialty pharma, growth equity</td>
        <td>Understands 505(b)(2) and specialty pharma economics; not in Veradermics</td>
    </tr>
    <tr>
        <td><strong>Sofinnova Partners</strong></td>
        <td>Life sciences generalist</td>
        <td>European fund with US deals; fresh perspective on market</td>
    </tr>
    <tr>
        <td><strong>Venrock Healthcare</strong></td>
        <td>Pharma, devices, services</td>
        <td>Broad healthcare mandate; not in Veradermics</td>
    </tr>
    <tr>
        <td><strong>Polaris Partners</strong></td>
        <td>Healthcare services</td>
        <td>503B outsourcing angle could interest them; services component</td>
    </tr>
    <tr>
        <td><strong>Great Point Partners</strong></td>
        <td>Healthcare services, specialty pharma</td>
        <td>Invests in healthcare services and specialty distribution</td>
    </tr>
    <tr>
        <td><strong>Vivo Capital</strong></td>
        <td>Biopharma, med devices</td>
        <td>Global perspective; Asia distribution opportunity</td>
    </tr>
</table>

<hr>

<h2>Outreach Strategy</h2>

<h3>Pitch Deck Key Messages</h3>

<div class="strategy-box">
    <h4 style="margin-top: 0;">1. Market Validation (1 slide)</h4>
    <ul>
        <li>Veradermics IPO: $256M raised, trading at premium</li>
        <li>Hair loss market: $4B+ and growing</li>
        <li>Oral minoxidil: 1,400+ patients in clinical literature, proven efficacy</li>
    </ul>

    <h4>2. Our Differentiation (2 slides)</h4>
    <ul>
        <li>Lipid matrix ≠ HPMC gel (different chemistry, mechanism, IP position)</li>
        <li>Strong freedom-to-operate analysis</li>
        <li>IPR petition ready to file (patent vulnerability)</li>
    </ul>

    <h4>3. Capital Efficiency (1 slide)</h4>
    <ul>
        <li>$8-21K to first human PK data</li>
        <li>8-10 weeks to proof-of-concept</li>
        <li>503A/503B = revenue without FDA approval</li>
    </ul>

    <h4>4. The Ask (1 slide)</h4>
    <ul>
        <li>Seed: $500K-1M for formulation optimization + initial compounding rollout</li>
        <li>Series A: $3-5M for multi-site compounding network + 505(b)(2) IND prep</li>
    </ul>
</div>

<h3>Contact Priority Order</h3>

<table>
    <tr>
        <th>Priority</th>
        <th>Fund</th>
        <th>Reason</th>
        <th>Warm Intro Needed?</th>
    </tr>
    <tr>
        <td>1</td>
        <td><strong>ARCH Venture Partners</strong></td>
        <td>Already in hair loss (Pelage); would diversify their bet</td>
        <td>Yes - try through Pelage network</td>
    </tr>
    <tr>
        <td>2</td>
        <td><strong>OrbiMed</strong></td>
        <td>Passed on Veradermics = may want competitive play</td>
        <td>Yes - healthcare banker intro</td>
    </tr>
    <tr>
        <td>3</td>
        <td><strong>Deerfield Management</strong></td>
        <td>Flexible structures; specialty pharma expertise</td>
        <td>Can cold outreach to BD team</td>
    </tr>
    <tr>
        <td>4</td>
        <td><strong>RA Capital</strong></td>
        <td>Loves differentiated science stories</td>
        <td>Yes - scientific advisor intro</td>
    </tr>
    <tr>
        <td>5</td>
        <td><strong>Frazier Healthcare</strong></td>
        <td>Specialty pharma expertise; growth stage fit</td>
        <td>Can cold outreach</td>
    </tr>
</table>

<hr>

<div class="recommendation">
    <h3>Recommended First Moves</h3>
    <ol>
        <li><strong>Complete formulation & human PK</strong> - Investors want data, not just a plan</li>
        <li><strong>Prepare 10-slide deck</strong> - Market, differentiation, team, capital efficiency, ask</li>
        <li><strong>Identify warm intros</strong> - Dermatologists, compounding pharmacists, healthcare bankers</li>
        <li><strong>Lead with ARCH or OrbiMed</strong> - Strategic motivation to compete with Veradermics</li>
        <li><strong>File IPR before fundraising close</strong> - Shows conviction and creates leverage</li>
    </ol>
</div>

<hr>

<h2>Competitive Intelligence Notes</h2>

<h3>Why OrbiMed Likely Passed on Veradermics</h3>

<div class="info-box">
    <p>OrbiMed is the largest healthcare-focused VC with $19B AUM. Their absence from Veradermics' cap table (despite being in virtually every major healthcare IPO) suggests they may have concerns about:</p>
    <ul>
        <li>Patent vulnerability (same concerns we've identified)</li>
        <li>Valuation (Veradermics raised at high valuations)</li>
        <li>Competition risk (generic minoxidil is $4/month)</li>
        <li>Reimbursement uncertainty (cosmetic vs. medical indication)</li>
    </ul>
    <p><strong>Pitch angle:</strong> "We address the concerns you likely had about Veradermics - different IP, capital-efficient path, proven drug."</p>
</div>

<h3>Why Eli Lilly Took a 4.9% Stake</h3>

<div class="strategy-box">
    <p>Eli Lilly's investment signals Big Pharma interest in the hair loss space. However, 4.9% is a "watching" position, not a committed acquirer. This creates opportunity:</p>
    <ul>
        <li>Other Big Pharma may want competitive exposure</li>
        <li>If Lilly acquires Veradermics, there's a market gap for alternatives</li>
        <li>Lilly's interest validates the market opportunity</li>
    </ul>
</div>

<hr>

<div class="source-list">
    <h4>Sources</h4>
    <ul>
        <li><a href="https://www.veradermics.com/2024-series-b/">Veradermics Series B Announcement</a></li>
        <li><a href="https://seekingalpha.com/news/4546829-hair-loss-pill-developer-veradermics-raises-2563m-in-upsized-ipo">Veradermics IPO - Seeking Alpha</a></li>
        <li><a href="https://pitchbook.com/profiles/company/442426-51">PitchBook - Veradermics Company Profile</a></li>
        <li><a href="https://news.crunchbase.com/public/veradermics-shares-soar-in-ipo/">Crunchbase - Veradermics IPO Analysis</a></li>
        <li><a href="https://www.ellty.com/blog/healthcare-investors">Top Healthcare VCs 2025</a></li>
        <li><a href="https://www.failory.com/blog/biotech-venture-capital-firms">Top Biotech VCs 2026</a></li>
        <li><a href="https://xtalks.com/biotech-funding-2025-tracker-follow-the-latest-raises-rounds-and-rd-momentum-4542/">Biotech Funding 2025 Tracker</a></li>
    </ul>
</div>

<hr>

<p style="text-align: center; color: #666;">
    <strong>Document prepared:</strong> February 5, 2026<br>
    <strong>Classification:</strong> Confidential - Fundraising Strategy<br>
    <em>Update investor status and outreach notes as conversations progress.</em>
</p>

</body>
</html>
